AmMax is a private biotechnology company focused on the clinical development of innovative oncology products. Under an exclusive worldwide license from Amgen, Inc., AmMax is leveraging positive proof-of-concept data and an improved safety profile to advance AMB-05X into the next phase of its clinical development program for tenosynovial giant cell tumor (TGCT). AmMax is initiating open-label dose optimization cohorts in its Phase 2 program to evaluate six months of treatment with its novel intra-articular therapy, followed by longer term monitoring.
AmMax Bio, Inc.
555 Twin Dolphin Drive
Suite 610
Redwood City, CA 94065